Nospharma
- Biotech or pharma, therapeutic R&D
Nospharma is an emerging pharmaceutical company focused on the development & commercialization of novel therapeutics for rare brain disorders and diseases. Our lead program, NOS-01, is a small-molecule combination therapy for Fragile X Syndrome that has an abbreviated clinical development plan and offers sustainable life-cycle management opportunities in 3 other rare CNS indications.
We are seeking meetings with potential partners for NOS-01, investors interested in joining our open Seed round (40% full, key milestone: IND clearance for Phase 2 PoC) and introductory conversations with Series A investors.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}